Perceptic has raised a $12m (£9m) seed round led by Accel, Air Street Capital and Elder Gull to accelerate its build of a single AI system to unify research, development and clinical decision-making across the drug lifecycle.
Drug development remains a complex and labor-intensive process, with decades of proprietary data, decisions and institutional knowledge kept within systems that were never designed to talk to each other.
Despite advances in frontier research, AI transformation approaches in pharma to date have primarily focused on building better tools or models to improve individual steps in isolation, leaving critical information fragmented across teams.
Perceptic’s platform strives to unify asset scouting, scientific evaluation and clinical data foundations on a shared intelligence layer. Its single system means insights are built on each other across research, development and clinical workflows.
The founding team made up of Tilman Flock, Martin Copes and Zaki Trache were behind Palantir’s AIP product and helped shape its life sciences practice.
“Too many critical decisions in drug development are still made without a complete view of the evidence,” says Flock, CEO and co-founder of Perceptic. “For years, the industry has tried to improve each part of the process separately, but that’s a linear process where insight dies at every handoff.
“The real shift comes from leveraging Perceptic’s mission control to make it recursively self-improving: connecting data, context and decision-making so every insight compounds.”
